BUZZ-Vertex rises after brokerage upgrade on kidney disease drug data

Reuters03-18
BUZZ-Vertex rises after brokerage upgrade on kidney disease drug data

** Shares of drugmaker Vertex Pharmaceuticals VRTX.O rise 1.1% to $463.96 premarket

** Brokerage Maxim Group upgrades Vertex to 'buy' from 'hold'; raises price target to $575 from no prior target, citing positive povetacicept data

** Co says interim late-stage data showed experimental kidney disease drug povetacicept met its main goal and all secondary goals in IgA nephropathy, a kidney disease that can lead to kidney failure

** Vertex plans to complete a rolling U.S. approval filing by end-March, with the brokerage expecting potential approval in late 2026 or early 2027

** Maxim says povetacicept could become a blockbuster and help diversify revenue beyond Vertex's cystic fibrosis drugs

** Shares up ~12% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment